eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for Colon Cancer and Rectal Cancer
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Radiation Therapy Compendium™ for Colon Cancer. These NCCN Guidelines® are currently available as Version 5.2024.
Link directly to the Updates section of the NCCN Guidelines: Colon Cancer
COL-C 1 of 6 through COL-C 6 of 6
- This section has been extensively revised and renamed: Principles of Surgery and Locoregional Therapies
- The following sub-sections have been added under Locoregional Therapies:
- Image Guided Tumor Ablation
- Liver Tumor Ablation
- Lung Tumor Ablation
- Arterially Directed Embolic Therapy
- Hepatic Transarterial Radioembolization (TARE) with Yttrium-90 (Y-90) Microspheres
- Transarterial Chemoembolization (TACE)
- External Beam Radiation Therapy (EBRT)
- Hepatic Arterial Infusion (HAI)
- References have been updated.
- The following sub-sections have been added under Locoregional Therapies:
COL-E 1 of 2
- Principles of Radiation and Chemoradiation Therapy
- Treatment Information
- Bullet 2 removed and added to COL-C: Consider SBRT for patients with oligometastatic disease.
- Bullets added:
- SBRT can be used alone or in conjunction with other metastatic-directed therapies for patients with oligometastatic disease. SBRT can be considered for larger lesions or more extensive disease, if there is sufficient uninvolved liver/lung and liver/lung radiation tolerance can be respected. There should be no other systemic disease or it should be minimal and addressed in a comprehensive management plan. RT dosing to consider, depending on the ability to meet normal organ constraints and underlying liver/lung function:
- SBRT: 30-60 Gy (typically in 3-5 fractions).
- Hypofractionation: 37.5-67.5 Gy in 10-15 fractions.
- SBRT can be used alone or in conjunction with other metastatic-directed therapies for patients with oligometastatic disease. SBRT can be considered for larger lesions or more extensive disease, if there is sufficient uninvolved liver/lung and liver/lung radiation tolerance can be respected. There should be no other systemic disease or it should be minimal and addressed in a comprehensive management plan. RT dosing to consider, depending on the ability to meet normal organ constraints and underlying liver/lung function:
- Treatment Information
MS-1
- The Discussion section has been updated to reflect the changes in the algorithm.
NCCN has published updates to the NCCN Guidelines and the NCCN Radiation Therapy Compendium™ for Rectal Cancer. These NCCN Guidelines are currently available as Version 4.2024.
Link directly to the Updates section of the NCCN Guidelines: Rectal Cancer
REC-C 1 of 8 through REC-C 8 of 8
- This section has been extensively revised and renamed: Principles of Surgery and Locoregional Therapies
- The following sub-sections have been added under Locoregional Therapies:
- Image Guided Tumor Ablation
- Liver Tumor Ablation
- Lung Tumor Ablation
- Arterially Directed Embolic Therapy
- Hepatic Transarterial Radioembolization (TARE) with Yttrium-90 (Y-90) Microspheres
- Transarterial Chemoembolization (TACE)
- External Beam Radiation Therapy (EBRT)
- Hepatic Arterial Infusion (HAI)
- References have been updated.
- The following sub-sections have been added under Locoregional Therapies:
REC-E 1 of 2
- Principles of Radiation Therapy
- Treatment Information
- Bullets added:
- SBRT can be used alone or in conjunction with other metastatic-directed therapies for patients with oligometastatic disease. SBRT can be considered for larger lesions or more extensive disease, if there is sufficient uninvolved liver/lung and liver/lung radiation tolerance can be respected. There should be no other systemic disease or it should be minimal and addressed in a comprehensive management plan. RT dosing to consider, depending on the ability to meet normal organ constraints and underlying liver/lung function:
- SBRT: 30-60 Gy (typically in 3-5 fractions).
- Hypofractionation: 37.5-67.5 Gy in 10-15 fractions.
- SBRT can be used alone or in conjunction with other metastatic-directed therapies for patients with oligometastatic disease. SBRT can be considered for larger lesions or more extensive disease, if there is sufficient uninvolved liver/lung and liver/lung radiation tolerance can be respected. There should be no other systemic disease or it should be minimal and addressed in a comprehensive management plan. RT dosing to consider, depending on the ability to meet normal organ constraints and underlying liver/lung function:
- Bullets added:
- Treatment Information
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.